These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12135583)

  • 21. Use of antimicrobial agents for community-acquired lower respiratory tract infections in hospitalised children.
    Esposito S; Blasi F; Allegra L; Principi N;
    Eur J Clin Microbiol Infect Dis; 2001 Sep; 20(9):647-50. PubMed ID: 11714047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthcare-associated pneumonia: diagnostic criteria and distinction from community-acquired pneumonia.
    Falcone M; Venditti M; Shindo Y; Kollef MH
    Int J Infect Dis; 2011 Aug; 15(8):e545-50. PubMed ID: 21616695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance.
    Galli L; Montagnani C; Chiappini E; de Martino M
    Acta Paediatr; 2013 Dec; 102(465):25-33. PubMed ID: 24330270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Appropriate antibiotic use for the respiratory tract infections].
    Miyashita N
    Yakugaku Zasshi; 2011; 131(10):1415-21. PubMed ID: 21963967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microbial etiology and bacterial resistance.
    Manresa F; Dorca J
    Semin Respir Infect; 1999 Jun; 14(2):115-27. PubMed ID: 10391406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermediate risk of multidrug-resistant organisms in patients who admitted intensive care unit with healthcare-associated pneumonia.
    Lee H; Park JY; Lee T; Lee YJ; Lim HJ; Park JS; Yoon HI; Lee JH; Lee CT; Cho YJ
    Korean J Intern Med; 2016 May; 31(3):525-34. PubMed ID: 26968189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.
    Shindo Y; Ito R; Kobayashi D; Ando M; Ichikawa M; Shiraki A; Goto Y; Fukui Y; Iwaki M; Okumura J; Yamaguchi I; Yagi T; Tanikawa Y; Sugino Y; Shindoh J; Ogasawara T; Nomura F; Saka H; Yamamoto M; Taniguchi H; Suzuki R; Saito H; Kawamura T; Hasegawa Y
    Am J Respir Crit Care Med; 2013 Oct; 188(8):985-95. PubMed ID: 23855620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial Resistance and Clinical Outcomes in Nursing Home-Acquired Pneumonia, Compared to Community-Acquired Pneumonia.
    Kang YS; Ryoo SR; Byun SJ; Jeong YJ; Oh JY; Yoon YS
    Yonsei Med J; 2017 Jan; 58(1):180-186. PubMed ID: 27873512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
    Segreti J; House HR; Siegel RE
    Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of aetiological tests for guiding antibiotic therapy in community-acquired pneumonia.
    Strålin K
    Int J Antimicrob Agents; 2008 Jan; 31(1):3-11. PubMed ID: 17920819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update on the pharmacotherapeutic management of lower respiratory tract infections.
    Cazzola M; Rogliani P; Aliberti S; Blasi F; Matera MG
    Expert Opin Pharmacother; 2017 Jul; 18(10):973-988. PubMed ID: 28480770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Barriers to the effective management of respiratory tract infections in the community.
    Saginur R
    Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relevance of healthcare-associated pneumonia for empirical antibiotic therapy in the Netherlands.
    Schweitzer VA; van Werkhoven CH; van Heijl I; Smits RF; Boel CHE; Bonten MJM; Postma DF; Oosterheert JJ
    Neth J Med; 2018 Nov; 76(9):389-396. PubMed ID: 30465653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M
    Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
    [No Abstract]   [Full Text] [Related]  

  • 37. Diagnostic testing to establish a microbial cause is helpful in the management of community-acquired pneumonia.
    Skerrett SJ
    Semin Respir Infect; 1997 Dec; 12(4):308-21. PubMed ID: 9436958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial therapy of community-acquired pneumonia.
    File TM; Niederman MS
    Infect Dis Clin North Am; 2004 Dec; 18(4):993-1016, xi. PubMed ID: 15555836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New trends in the prevention and management of community-acquired pneumonia.
    Postma DF; van Werkhoven CH; Huijts SM; Bolkenbaas M; Oosterheert JJ; Bonten MJ
    Neth J Med; 2012 Oct; 70(8):337-48. PubMed ID: 23065981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of fluoroquinolones in respiratory tract infections: community acquired pneumonia.
    García-Rodríguez JA; Muñoz Bellido JL
    Int J Antimicrob Agents; 2000 Nov; 16(3):281-5. PubMed ID: 11091048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.